Yourgene has made a strong start to FY22, benefitting from the investments made in FY21. Q1 revenues are up 80% to >£6.0m, a record performance, driven by a return of the core business (+30%) and renewed momentum around Covid-19 testing. Delays to mobilising new clients are easing and Yourgene has signed a number of notable contracts in recent months with blue chip partners. These should contribute materially in time, providing a strong underpinning for a multi-year growth story. We leave our fo ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Investment in FY21 starting to pay off in Q122
- Published:
11 Aug 2021 -
Author:
Chris Glasper -
Pages:
3
Yourgene has made a strong start to FY22, benefitting from the investments made in FY21. Q1 revenues are up 80% to >£6.0m, a record performance, driven by a return of the core business (+30%) and renewed momentum around Covid-19 testing. Delays to mobilising new clients are easing and Yourgene has signed a number of notable contracts in recent months with blue chip partners. These should contribute materially in time, providing a strong underpinning for a multi-year growth story. We leave our fo ....